1. Metabolic Enzyme/Protease
    Neuronal Signaling
  2. COMT
  3. Entacapone sodium salt

Entacapone sodium salt 

Cat. No.: HY-14280A
Handling Instructions

Entacapone is a specific, potent, peripherally acting catechol-O-methyltransferase (COMT) inhibitor with IC50 of 151 nM for PD treatment.

For research use only. We do not sell to patients.

Entacapone sodium salt Chemical Structure

Entacapone sodium salt Chemical Structure

CAS No. : 1047659-02-8

Size Price Stock
10 mg USD 60 Ask For Quote & Lead Time
50 mg USD 120 Ask For Quote & Lead Time
100 mg USD 180 Ask For Quote & Lead Time

* Please select Quantity before adding items.

Other In-stock Forms of Entacapone sodium salt:

Other Forms of Entacapone sodium salt:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Entacapone is a specific, potent, peripherally acting catechol-O-methyltransferase (COMT) inhibitor with IC50 of 151 nM for PD treatment. IC50 Value: 151 nM Target: COMT in vitro: Entacapone inhibits catechol-O-methyltransferase(COMT) with similar IC50 in different tissues including live, duodenum, kidney and lung, but entacapone is more active than tolcapone in those tissues. Entacapone (< 100 μM) is a potent inhibitor of α-syn and β-amyloid (Aβ) oligomerization and fibrillogenesis, and also protects against extracellular toxicity induced by the aggregation of both proteins in PC12 cells. in vivo: Levodopa/carbidopa/entacapone has been shown to improve the pharmacokinetic profile of levodopa and provide superior symptomatic control compared with conventional levodopa/dopa decarboxylase inhibitor therapy. We report four case histories describing clinical experience of using levodopa/carbidopa/entacapone 200/50/200 mg, one of the latest doses of this formulation, in a range of patients with Parkinson's disease. These cases illustrate that levodopa/carbidopa/entacapone 200/50/200 mg provides improvements in symptomatic control. Clinical trial: The combination product carbidopa/levodopa/entacapone (CLE) was approved in 2003 for the treatment of PD patients.

Clinical Trial
Molecular Weight

327.27

Formula

C₁₄H₁₄N₃NaO₅

CAS No.

1047659-02-8

SMILES

O=C(N(CC)CC)/C(C#N)=C/C1=CC([N+]([O-])=O)=C([O-])C(O)=C1.[Na+]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

EntacaponeCOMTCatechol-O-methyltransferaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product name:
Entacapone sodium salt
Cat. No.:
HY-14280A
Quantity:
MCE Japan Authorized Agent: